MARKET

ARVN

ARVN

Arvinas
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.01
+1.84
+7.31%
After Hours: 27.00 -0.01 -0.04% 17:59 12/04 EST
OPEN
25.30
PREV CLOSE
25.17
HIGH
27.09
LOW
25.00
VOLUME
476.06K
TURNOVER
--
52 WEEK HIGH
61.57
52 WEEK LOW
19.68
MARKET CAP
1.10B
P/E (TTM)
-10.4386
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Arvinas to Participate in Upcoming Virtual Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences:
GlobeNewswire · 11/25 12:04
Arvinas to Participate in Upcoming Virtual Investor Conferences
NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020. A pre-recorded fireside chat held with John Houston, Ph.D., President and Chief Executive Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, is available here and on the Events + Presentations section of the Company’s website.3rd Annual Evercore ISI HealthCONx Virtual Conference on Thursday, December 3, 2020. Ian Taylor, Ph.D., Chief Scientific Officer, and Randy Teel, Ph.D., Vice President of Corporate Development, will participate in a fireside chat at 8:50 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.About Arvinas Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.Contacts for Arvinas Investors Will O’Connor, Stern Investor Relations ir@arvinas.comMedia Kirsten Owens, Arvinas Communications kirsten.owens@arvinas.com
GlobeNewswire · 11/25 12:00
New Strong Sell Stocks for November 16th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Zacks · 11/16 14:21
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial -
GlobeNewswire · 11/05 12:01
Rock star Growth Puts Arvinas (NASDAQ:ARVN) In A Position To Use Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Simply Wall St. · 11/05 10:52
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
Organogenesis Holdings, Anavex Life Sciences leads healthcare gainers; Vertex Pharmaceuticals, Aphria among major losers
Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cyclerion Therapeutics (CYCN) -13%, Liquidia Technologies (LQDA) -9%, Arvinas (ARVN) -7%.
Seekingalpha · 10/15 15:12
Arvinas discloses five additional preclinical programs
Arvinas ([[ARVN]] +1.6%) has announced platform updates and disclosed five additional programs from its preclinical pipeline, utilizing its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein
Seekingalpha · 10/14 13:51
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARVN. Analyze the recent business situations of Arvinas through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARVN stock price target is 57.80 with a high estimate of 78.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 191
Institutional Holdings: 38.99M
% Owned: 96.15%
Shares Outstanding: 40.55M
TypeInstitutionsShares
Increased
46
3.81M
New
42
-375.44K
Decreased
39
3.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Oto Brasil Cavalcante
Chairman/Independent Director
Timothy Shannon
Chief Executive Officer/Director
Ari Cavalcante Neto
President/Chief Executive Officer/Director
John Houston
Chief Financial Officer/Vice President - Business Development
David Dos Santos
Chief Financial Officer
Sean Cassidy
Chief Operating Officer
Joao Silva
Chief Scientific Officer
Ian Taylor
Other
Ronald Peck
Director
Linda Bain
Independent Director
Martin Escobari
Director
Laurie Alsup
Director
Wendy Dixon
Independent Director
Alberto Menache
Independent Director
Edward Kennedy
Independent Director
Bradley Margus
Independent Director
Briggs Morrison
Independent Director
Leslie Norwalk
Independent Director
Liam Ratcliffe
Independent Director
Laurie Smaldone Alsup
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARVN
Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arvinas Inc stock information, including NASDAQ:ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.